Advertisement

CQ30. What Are Prognostic Factors of Medullary Carcinoma?

  • Shinya Uchino
  • Daishu Miura
  • Takahiro Okamoto
Chapter

Abstract

Since serum CEA and calcitonin levels are sensitive tumor markers of medullary thyroid carcinoma, they can be used not only on the evaluation of carcinoma relapse that is manifest and tangible on physical findings and imaging studies, but also on biochemical relapses in which these laboratory data are the measure of treatment outcomes [1, 2]. The literature was surveyed regarding prognostic factors for these outcomes.

Keywords

Prognostic Factor Medullary Thyroid Carcinoma Recurrent Case Extrathyroid Extension Calcitonin Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Schröder S, Böcker W, Baisch H et al (1988) Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 61:806–816 (RS)PubMedCrossRefGoogle Scholar
  2. 2.
    Takami H, Bessho T, Kameya T et al (1988) Immunohistochemical study of medullary thyroid carcinoma: relationship of clinical features to prognostic factors in 36 patients. World J Surg 12:572–579 (RS)PubMedCrossRefGoogle Scholar
  3. 3.
    Laupacis A, Wells G, Richardson WS et al (1994) Users’ guides to the medical literature. V. How to use an article about prognosis. JAMA 272:234–237PubMedCrossRefGoogle Scholar
  4. 4.
    Scopsi L, Sampietro G, Boracchi P et al (1996) Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. Cancer 78:2173–2183 (RS)PubMedCrossRefGoogle Scholar
  5. 5.
    Hyer SL, Vini L, A’Hern R et al (2000) Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol 26:686–690 (RS)PubMedCrossRefGoogle Scholar
  6. 6.
    Gülben K, Berberĝlu U, Boyabalti M (2006) Prognositc factors for sporadic medullary thyroid carcinoma. World J Surg 30:84–90 (RS)PubMedCrossRefGoogle Scholar
  7. 7.
    Raue F, Kotzerke J, Reinwein D et al (1993) Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Meullary Thyroid Carcinoma Register. Clin Invest 71:7–12 (RS)CrossRefGoogle Scholar
  8. 8.
    Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs à calcitonine. Clin Endocrinol (Oxf) 48:265–273 (RS)CrossRefGoogle Scholar
  9. 9.
    Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134–2142 (RS)PubMedCrossRefGoogle Scholar
  10. 10.
    Fleming JB, Lee JE, Bouvet M et al (1999) Surgical strategy for the trement of medullary thyroid carcinoma. Ann Surg 230:697–707 (RS)PubMedCrossRefGoogle Scholar
  11. 11.
    Weber T, Schilling T, Frank-Raue K et al (2001) Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130:1044–1049 (RS)PubMedCrossRefGoogle Scholar
  12. 12.
    Scollo C, Baudin E, Travagli JP et al (2003) Rationale for central and bilateral lymph node diseectin in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88:2070–2075 (RS)PubMedCrossRefGoogle Scholar
  13. 13.
    Machens A, Schneyer U, Holzhaused HJ et al (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:2029–2034PubMedCrossRefGoogle Scholar
  14. 14.
    Miyauchi A, Onishi T, Morimoto S et al (1984) Relation of doubling time f plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 199:461–466 (RS)PubMedCrossRefGoogle Scholar
  15. 15.
    Barbet J, Campion L, Kraeber-Bodéré F et al (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077–6084 (RS)PubMedCrossRefGoogle Scholar
  16. 16.
    Giraudet AL, Ghulzan AA, Aupérin A et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239–246 (RS)CrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  1. 1.Department of SurgeryNoguchi Thyroid Clinic and Hospital FoundationBeppuJapan
  2. 2.Department of Breast and Endocrine SurgeryToranomon HospitalTokyoJapan
  3. 3.Department of Endocrine Surgery and Hygiene & Public Health IITokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations